TERRY JORDAN: Open Payments
NPI 1417046327 · MERIDIAN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,276 in 63 payments from 11 companies in 2025. Trend: 2023 $650 · 2024 $908 · 2025 $1,276
Food & beverage: $1,276
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $300 |
| ABBVIE INC. | 12 | $229 |
| Neurocrine BioSciences, Inc. | 7 | $144 |
| E.R. Squibb & Sons, L.L.C. | 7 | $126 |
| Vanda Pharmaceuticals Inc. | 4 | $96 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Lundbeck LLC | 3 | $61 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, COBENFY, FANAPT, REXULTI, AUSTEDO XR, Auvelity.
Industry payments across MS — which companies pay providers there.
